Skip Navigation
Search Menu
Find an Expert

 


Evan Jacob Lipson, M.D.

Photo of Dr. Evan Jacob Lipson, M.D.

Assistant Professor of Oncology

Male

Expertise: Medical Oncology

Research Interests: Melanoma; Immunotherapy

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-616-7660

401 N. Broadway
Weinberg Building
Baltimore, MD 21231 map
Phone: 410-955-8893
Fax: 410-955-8587

Sibley Memorial Hospital
Appointment Phone: 202-660-6500

5255 Loughboro Road NW
Washington, DC 20016 map

Background

Dr. Evan J. Lipson is a medical oncologist at Sibley Memorial Hospital, as well as an assistant professor of oncology at Johns Hopkins University School of Medicine. Dr. Lipson is board certified in internal medicine and medical oncology. He practices out of Sibley Memorial Hospital in Washington, D.C. and the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Md.

Dr. Lipson has an expertise in melanoma and immunotherapy.

Dr. Lipson earned his undergraduate degree from the University of Maryland and his medical degree from Mount Sinai School of Medicine. He completed a residency in internal medicine at Johns Hopkins University School of Medicine, as well as a fellowship in hematology and oncology. 

Dr. Lipson is the founder of SeizeTheDays.org, a non-profit organization that chronicles the stories of cancer patients who find interesting and meaningful ways to add life to their days.

Dr. Lipson has contributed to numerous clinical trials, publications and presentations. His research focuses on investigating new therapies for patients with various stages of melanoma, ranging from preventing disease recurrence in high-risk patients to developing innovative drug therapies for patients with advanced disease. Dr. Lipson works to optimize combinations of immune-based therapies, such as cancer vaccines and immune checkpoint inhibitors, in order to achieve maximal anti-tumor activity. As a part of the Melanoma and Immunotherapy programs, Dr. Lipson also collaborates with basic and translational scientists in order to investigate biomarkers of drug efficacy.

...read more

Titles

  • Assistant Professor of Oncology

Departments / Divisions

  • Medicine at Sibley Memorial Hospital
  • Oncology - Medical Oncology

Education

Degrees

  • MD, Mount Sinai School of Medicine (2005)

Residencies

  • Johns Hopkins University School of Medicine / Medicine (2008)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2011)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2008)
  • American Board of Internal Medicine / Medical Oncology (2010)

Research & Publications

Selected Publications

Evan J. Lipson, M.D., is a melanoma specialist at the Johns Hopkins Kimmel Cancer Center. His research focuses on investigating new therapies for patients with various stages of melanoma, ranging from preventing disease recurrence in high-risk patients to developing innovative drug therapies for patients with advanced disease. Dr. Lipsons concentration is in optimizing combinations of immune-based therapies, such as cancer vaccines and immune checkpoint inhibitors, in order to achieve maximal anti-tumor activity. As a part of the Melanoma and Immunotherapy programs, Dr. Lipson also collaborates with basic and translational scientists in order to investigate biomarkers of drug efficacy.

Dr. Lipson is also the founder of SeizeTheDays.org, a non-profit organization which chronicles the stories of cancer patients who, with spirit and determination, find interesting and meaningful ways to add life to their days.



1: Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011 Nov 15;17(22):6958-62. Epub 2011 Sep 7. PubMed PMID: 21900389.

2: Goyal J, Lipson EJ, Rezaee N, Edil BH, Schulick R, Wolfgang CL, Hruban RH, Antonarakis ES. Surgical Resection of Malignant Melanoma Metastatic to the
Pancreas: Case Series and Review of Literature. J Gastrointest Cancer. 2011 Sep 13. [Epub ahead of print] PubMed PMID: 21912850.

3: Lipson EJ. Art in oncology: how patients add life to their days. J Clin Oncol. 2011 Apr 1;29(10):1392-3. Epub 2011 Feb 7. PubMed PMID: 21300935.

4: Lipson EJ, Taube JM, Chen L, Topalian SL. Anti-PD-1 and anti-B7-H1/PD-L1 monoclonal antibody therapies. In: Targeted Therapeutics in Melanoma, Gajewski TF and Hodi FS (eds). New York: Humana Press. 2011.

5: Lipson EJ, Huff CA, Holanda DG, McDevitt MA, Fine DM. Lenalidomide-induced acute interstitial nephritis. Oncologist. 2010;15(9):961-4. Epub 2010 Aug 13. PubMed PMID: 20709889.

6: Lipson EJ, Fiel MI, Florman SS, Korenblat KM. Patient and graft outcomes following liver transplantation for sarcoidosis. Clin Transplant. 2005
Aug;19(4):487-91. PubMed PMID: 16008593.

Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective re-induction therapy with an anti-PD-1 antibody. Clinical Cancer Research, 2013;19(2):462-8.

Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL, Taube JM. PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunology Research, 2013;1(2):1-10.

Lipson EJ. Art in oncology: How patients add life to their days. Journal of Clinical Oncology. 2011;29(10):1392–3.

Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research. 2011;17(22):6958-62.

Lipson EJ, Taube JT, Chen L, Topalian SL. Anti-PD-1 and B7-H1/PD-L1 monoclonal antibodies. In: Targeted Therapeutics in Melanoma, Gajewski T and Hodi FS (eds). New York: Humana Press, 2012, pp. 291-306.

Lipson EJ. Re-orienting the Immune System: Durable Tumor Regressions and Successful Re-induction Therapy with Anti-PD-1. OncoImmunology. 2013;2(4): eLocation ID: e23661.

Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplant patients with metastatic melanoma. Journal of Clinical Oncology. In press, 2013.

Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA, Vogelstein B, Nowak MA. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife, 2013;2:e00747

Lipson EJ, Topalian SL. From Discovery to Development: Blockade of PD-1 and its Ligands. Melanoma Letter. 2013:31(2):4-7.

Ruzevick J, Nicholas S, Redmond K, Kleinberg LR, Lipson EJ, Lim M. A patient with HIV treated with ipilimumab and stereotactic radiosurgery for melanoma metastases to the brain. Case Reports in Oncological Medicine. In press, 2013.

Truong H, Sundi D, Sopko N, Xing D, Lipson EJ, Bivalacqua TJ. A case report of primary recurrent malignant melanoma of the urinary bladder. Urology Case Reports. In press, 2013.

Drake CG, Lipson EJ, Brahmer JR. Breathing New Life into Immunotherapy: An Update on Immune Approaches to Lung Cancer, Kidney Cancer, and Melanoma. Nature Reviews Clinical Oncology. In press, 2013.

Goyal J, Lipson EJ, Rezaee N, Edil BH, Schulick R, Wolfgang CL, Hruban RH, Antonarakis ES. Surgical resection of malignant melanoma metastatic to the pancreas: Case series and review of literature. J Gastrointest Cancer. 2011;2011:13.

Is this you? Edit Profile